The threat to this critical medicine deepens. We have to act fast to protect glutathione. Action Alert! Ahead of the June 8th meeting of an FDA advisory committee, the FDA has released its own recommendation for whether glutathione should be permitted to be made at specialized pharmacies for individual patients—and the news isn’t good. The agency has recommended that compounded glutathione be banned from pharmacy compounding. We need to work fast to make sure the FDA and its committee knows that patient health will be harmed if we do not have access to compounded glutathione. Read more.